Wave Life Sciences WVE US — Income Tax Reconciliation Tax Credits Research

Similar metrics at other companies

GRMNUS — Income Tax Reconciliation Tax Credits Research

$8.63M-9.7%

IONSIncome Tax Reconciliation Tax Credits Research

$4.44M—

RBCIncome Tax Reconciliation Tax Credits Research

$600K-4.0%

GRMNUS — Effective Income Tax Rate Reconciliation Tax Credits Research

-0.4%-0.1pp

PAYCA — Income Tax Reconciliation Tax Credits Research

-$634.75K—

MECEffective Income Tax Rate Reconciliation, Tax Credit, Research, Amount

$611K+219%

Other financials

Income statement

See full

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Balance sheet

See full

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total equity$511.7M+198%

Total assets$583.5M+102%

Cash flow

See full

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Valuation

See full

Market cap$1.11B+9.2%

Enterprise value$577.44M-27.2%

P/S14.6×-11.8×

Profitability

See full

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Returns & leverage

See full

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.

The official record: Wave Life Sciences’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's us — income tax reconciliation tax credits research.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Wave Life Sciences's US — income tax reconciliation tax credits research?: Wave Life Sciences (WVE) reported US — income tax reconciliation tax credits research of -$1.24M in Q4 2025.
What does US — income tax reconciliation tax credits research mean?: This metric quantifies the dollar value of tax credits claimed by the US segment specifically for research and development activities. It reflects the company's ability to leverage government incentives to offset tax liabilities through innovation investment. This is a key indicator of the tax-shield benefits derived from the company's R&D-heavy business model.